FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM

被引：111

作者：

BROSEN, K

SKJELBO, E

机构：

[1] Research Center, Orion Pharmaceutica, Espoo

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 32卷 / 01期

关键词：

D O I：

10.1111/j.1365-2125.1991.tb05630.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

收藏

页码：136 / 137

页数：2

相关论文

共 15 条

[1] ARANOW RB, 1989, AM J PSYCHIAT, V146, P911
[2] FLUOXETINE KINETICS AND PROTEIN-BINDING IN NORMAL AND IMPAIRED RENAL-FUNCTION
ARONOFF, GR
BERGSTROM, RF
POTTRATZ, ST
SLOAN, RS
WOLEN, RL
LEMBERGER, L
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (01) : 138 - 144
[3] FLUOXETINE INDUCES ELEVATION OF DESIPRAMINE LEVEL AND EXACERBATION OF GERIATRIC NONPSYCHOTIC DEPRESSION
BELL, IR
COLE, JO
[J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1988, 8 (06) : 447 - 448
[4] BORSEN K, 1991, IN PRESS THER DRUG M
[5] IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE
BROSEN, K
OTTON, SV
GRAM, LF
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) : 543 - 549
[6] CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM
BROSEN, K
GRAM, LF
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) : 537 - 547
[7] BROSEN K, 1991, IN PRESS CLIN PHARM
[8] COWLEY G, 1990, NEWSWEEK 0326
[9] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT
EICHELBAUM, M
SPANNBRUCKER, N
STEINCKE, B
DENGLER, HJ
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) : 183 - 187
[10] A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION
EVANS, DAP
MAHGOUB, A
SLOAN, TP
IDLE, JR
SMITH, RL
[J]. JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) : 102 - 105